GlassScriptPhysician profile
Scott Krankkala
NPI 1548781438
$2,660.78
in general payments reported to CMS, 2019-2025
19 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $710 · 2023: $765 · 2024: $465 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,401.43 | 2021-2025 | Resonate El Icd Vr, Watchman Flx, Emblem Mri S-Icd |
| Edwards Lifesciences Corporation | $268.89 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.47 | 2021-2024 | Lifevest |
| Elutia, INC. | $200.00 | 2021 | |
| Chiesi USA, INC. | $154.83 | 2021-2022 | |
| Philips North America LLC | $126.15 | 2023 | |
| Pfizer INC. | $55.83 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $28.16 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $26.28 | 2024 | Uptravi, Opsumit |
| Medtronic, INC. | $21.40 | 2022 | |
| Novo Nordisk INC | $21.01 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.11 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.73 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $16.94 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.39 | 2024 | Amvuttra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $14.37 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.23 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $13.36 | 2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $13.20 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Krankkala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.